Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14427907 | 1.00 | KMT2A (0.40) | KMT2APLA2G2CALDH1A1TSHRGAA | |
| SCHEMBL25602953 | 0.87 | KMT2A (0.42) | KMT2APLA2G2CALDH1A1TSHRGAA | |
| SCHEMBL11107976 | 0.83 | PMP22 (0.38) | KMT2APLA2G2CALDH1A1TSHRGAA | |
| SCHEMBL13599749 | 0.82 | ENPEP (0.31) | — | |
| Hydrochloric Acid SCHEMBL11103201 | 0.82 | PMP22 (0.37) | KMT2APLA2G2CALDH1A1TSHRGAA | |
| SCHEMBL19368952 | 0.82 | GCLC (0.33) | — | |
| SCHEMBL26724515 | 0.80 | KMT2A (0.38) | KMT2APLA2G2CALDH1A1TSHRGAA | |
| SCHEMBL17641649 | 0.80 | PLA2G2C (0.37) | KMT2APLA2G2CALDH1A1TSHRGAA | |
| SCHEMBL15386549 | 0.79 | KMT2A (0.35) | KMT2APLA2G2CALDH1A1TSHRGAA | |
| SCHEMBL13707723 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321048-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | MERSANA THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230285578-A1 | PTH ANALOGS FOR THE TREATMENT OF HYPOPARATHYROIDISM | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230172910-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | MERSANA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200369728-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20200289609-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| WO-2017205786-A1 | CELL PERMEABLE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
| US-20170114098-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114098-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170107252-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. | 2017-04-20 | — | — | US | disclosed |
| US-20170107252-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. | 2017-04-20 | — | — | US | disclosed |
| US-20170037086-A1 | PEPTIDOMIMETIC MACROCYCLES WITH PTH ACTIVITY | AILERON THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037086-A1 | PEPTIDOMIMETIC MACROCYCLES WITH PTH ACTIVITY | AILERON THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170002042-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170002042-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285578-A1 | PTH ANALOGS FOR THE TREATMENT OF HYPOPARATHYROIDISM | PTH1R, PTMS, THRA | KMT2A 2892/4885PLA2G2C 193/4885ALDH1A1 4508/4885 |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | KMT2A 3232/4885PLA2G2C 3210/4885ALDH1A1 2219/4885 |
| US-20200369728-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | NGLY1, BID, DNPEP | KMT2A 4194/4885PLA2G2C 2311/4885ALDH1A1 4647/4885 |
| US-20230321048-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | STING1, CGAS, IFNAR1 | KMT2A 2297/4885PLA2G2C 1029/4885ALDH1A1 2462/4885 |
| US-20230172910-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | STING1, CGAS, IFNAR1 | KMT2A 2297/4885PLA2G2C 1029/4885ALDH1A1 2462/4885 |
| US-20200289609-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | MPL, MUC1, FLT3 | KMT2A 2765/4885PLA2G2C 1812/4885ALDH1A1 4558/4885 |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | FLT3, BID, GRPR | KMT2A 3973/4885PLA2G2C 779/4885ALDH1A1 4687/4885 |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | KMT2A 3232/4885PLA2G2C 3210/4885ALDH1A1 2219/4885 |
| US-20170002042-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | KMT2A 3890/4885PLA2G2C 3206/4885ALDH1A1 4850/4885 |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | VIP, IAPP, NGLY1 | KMT2A 4633/4885PLA2G2C 790/4885ALDH1A1 4866/4885 |
| US-20170114098-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | NGLY1, BID, DNPEP | KMT2A 4194/4885PLA2G2C 2311/4885ALDH1A1 4647/4885 |
| US-20170037086-A1 | PEPTIDOMIMETIC MACROCYCLES WITH PTH ACTIVITY | PTH1R, CALCA, CALCB | KMT2A 4209/4885PLA2G2C 404/4885ALDH1A1 4856/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | KMT2A 3232/4885PLA2G2C 3210/4885ALDH1A1 2219/4885 |
| US-20170107252-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | MCL1, BCL2L1, BCL2L11 | KMT2A 1485/4885PLA2G2C 3143/4885ALDH1A1 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.